Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications.

Immunoadsorption is well known to selectively remove immunoglobulins and immune complexes from plasma and is applied in a variety of autoimmune diseases and for desensitization before, or at acute rejection after organ transplantation. Performance, safety, and clinical effectiveness of immunoadsorption were the aim of this study. This prospective, noninterventional, multicentre cohort study included patients treated with immunoadsorption (Immunosorba or GLOBAFFIN adsorbers) for any indication. Clinical effectiveness was assessed after termination of the patient's individual treatment schedule. Eighty-one patients were included, 69 were treated with Immunosorba, 11 with GLOBAFFIN, one patient with both adsorbers. A majority of patients was treated for neurological indications, dilated cardiomyopathy, and before or after kidney or heart transplantation. Mean IgG reduction from pre- to post-treatment was 69.9% ± 11.5% for Immunosorba and 74.1% ± 5.0% for GLOBAFFIN, respectively. The overall IgG reduction over a complete treatment block was 68%-93% with Immunosorba and 62%-90% with GLOBAFFIN depending on the duration of the overall treatment. After termination of the immunoadsorption therapy, an improvement of clinical status was observed in 63.0%, stabilization of symptoms in 29.6%, and a deterioration in 4.9% of patients. Changes in fibrinogen, thrombocytes, and albumin were mostly classified as noncritical. Overall, the treatments were well tolerated. Immunoadsorption in routine clinical practice with both GLOBAFFIN and Immunosorba has been safely performed, was well tolerated by patients, and effective in lowering immunoglobulins with an improvement or maintenance of clinical status, thus represents an additional therapeutic option for therapy refractory immune disorders.

Papillary renal cell carcinoma in the transplanted kidney - a case report focusing on contrast enhanced ultrasound features.

The purpose of the case report is to show that contrast enhanced ultrasound (CEUS) is an important imaging modality for patients with impaired renal function in detecting, characterizing and excluding renal cell carcinoma (RCC) in transplanted kidneys. To our knowledge this is the first report of CEUS in a tumour of a kidney transplant. CEUS is feasible, reveals comparable results to computed tomography and should be concerned as the method of choice for patients with impaired renal function like renal graft recipients.

Abdominal pseudocysts following peritoneal dialysis-associated peritonitis: a report of 3 cases.

Common complications of peritoneal dialysis are peritonitis, leakages, hernias, catheter dislocation, and loss of ultrafiltration. We describe 3 cases of abdominal pseudocysts with progressive difficulty instilling and draining peritoneal dialysis fluid. The 3 patients had been treated with peritoneal dialysis for 1, 2, and 6 years. Two patients had experienced previous episodes of peritonitis and 1 had signs of peritonitis when the pseudocyst was first detected. In all 3 patients, ultrasound and computed tomographic scans, obtained because of progressive decreases in solute clearance, showed dialysate entrapped in a cyst that enclosed the inner tip of the Tenckhoff catheter. The cyst was resected in 2 patients, and the Tenckhoff catheter was removed in 1 patient. Histologic samples were not suggestive of encapsulating peritoneal sclerosis. Abdominal pseudocysts are a rare complication after peritoneal dialysis therapy, but are reported in 1% of patients with ventriculoperitoneal shunts. The outcome of our described patients was good, although they had to be switched to hemodialysis therapy.